The deals collection - January 2019

We bring together recent therapy and technology features, based upon some of January's largest biopharma deals.

Like Comment

Before attendees had even arrived at the hotly anticipated annual JP Morgan conference, Bristol-Myers Squibb (BMS) kicked off dealmaking in style in early January by announcing its $74 billion acquisition of Celgene. The merger is set to create a major force in oncology by bringing together BMS’ extensive immuno-oncology (IO) pipeline and Celgene’s blood cancer portfolio, which includes potential CAR-T therapies gained in Celgene’s $9 billion purchase of Juno—one of last year’s biggest IO deals. Oncology dealmaking then made the headlines again a few days later as Lilly announced its $8 billion takeover of Loxo Oncology, a pioneer in the development of cancer drugs for tissue-agnostic indications.

Given Celgene’s prolific partnering history, concerns have been raised about the long-term impact of its departure from the biotech ecosystem. Nevertheless, Celgene continued dealmaking during January, paying Kyn Therapeutics $80 million upfront and undisclosed milestones for options to license two of its preclinical IO programs, targeting the aryl hydrocarbon receptor and kynurenine-degrading enzyme, respectively. On the same day the company also penned a preclinical collaboration with Obsidian Therapeutics to develop potential CAR-T cell therapy candidates incorporating its destabilizing domain technology, before finishing up the month with a potential $980 million deal with Triphase Accelerator for the option to license TRPH-395, a preclinical small molecule targeting WDR5 for blood cancers.

Elsewhere, dealmaking momentum in the gene therapy field continues to build following the recent pioneering product approvals, with a number of collaborations being announced in January. In the gene-editing field, Vertex regained some rights for two DNA-dependent protein kinase inhibitors that it licensed to Merck KGaA in 2017 in a $230 million deal focused on oncology. Under the undisclosed terms of the latest deal, Vertex will be able to use the two compounds for CRISPR-based gene editing applications in six genetic disease areas, whilst Merck KGaA will continue to develop the candidates in oncology.

Following this, in a deal potentially worth $1.8 billion— including a $165 million upfront payment —Neurocrine Biosciences acquired development and commercialization rights to four gene therapy programs from Voyager Therapeutics. The deal includes VY-AADC, a phase 2 asset for Parkinson’s disease, and VY-FXN01, which is in preclinical development for Friedreich’s ataxia. Both gene therapies are based on the adeno-associated virus vector (AAV) platform.

Wrapping January up, Janssen Pharmaceuticals teamed up with MeiraGTX to develop and commercialize AAV-based gene therapies for the treatment of inherited retinal diseases. Janssen will pay MeiraGTX $100 million upfront, and up to $340 million in potential milestones to gain commercialization rights to any developed candidates. 

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 15 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

1 Comments

Go to the profile of Matthew Jones
Matthew Jones over 1 year ago

Thanks @Raveena certainly a kick start to the year for the industry. We appreciate the roundups. Keep them coming.